Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Novo Nordisk has initiated two trials investigating the efficacy of semaglutide 7.2mg, STEP UP and STEP UP T2D. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group ...

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...

“Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide ...

With sales of Novo Nordisk’s obesity blockbuster Wegovy ... obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic—accelerated rapidly in 2024’s ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic for diabetes, were key to its earnings beat.

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too ... And the inclusion of the semaglutide drugs — Wegovy for weight loss and Ozempic for diabetes, as well as an older semaglutide drug, Rybelsus ...

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...

And here's the kicker: Three weight loss drugs from Novo Nordisk top this list. Taking aim at the sky-high price of semaglutide, Medicare plans to negotiate prices for Novo Nordisk products ...

Novo Nordisk reported $40.5 billion in sales for ... The strong performance was driven by the company's pair of semaglutide drugs, Wegovy and Ozempic. Of the full year's total sales of $40.5 ...